Anti-rheumatoid arthritis 33 antibody

RA33 is the core protein A2 of the heterogeneous ribonucleoprotein body (hnRNP). RA33 is associated with RA and is not associated with RF. Due to poor specificity, limitations due to methodological or specific antigen sources are currently not used in routine clinical diagnosis. The anti-RA33 sensitivity to RA diagnosis varies from country to country, mostly between 20% and 40%, with a maximum of 61% and a minimum of 6%. Its specificity was originally reported to be 99.6%. However, studies have shown that this antibody can also be detected in 10% to 40% of diseases such as SLE. Anti-RA33 positive has an early indication of RA, and AKA has a significant correlation with anti-RA33. The combination of the two can improve the sensitivity of RA diagnosis and also help early diagnosis. The RA33 antibody was not associated with RF, and the positive rate of RA33 antibody in RF-negative patients was 27% to 45%. Those with positive anti-RA33 were milder, but whether they showed self-limiting and good prognosis, further study is needed. Basic Information Specialist classification: growth and development check classification: immunological examination Applicable gender: whether men and women apply fasting: not fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: Tips for rheumatism. Tips: A small number of SSc are positive. Normal value negative. Clinical significance The anti-RA33 sensitivity to RA diagnosis varies from country to country, mostly between 20% and 40%, with a maximum of 61% and a minimum of 6%. Its specificity was originally reported to be 99.6%. However, studies have shown that this antibody can also be detected in 10% to 40% of diseases such as SLE. Anti-RA33 positive has an early indication of RA, and AKA has a significant correlation with anti-RA33. The combination of the two can improve the sensitivity of RA diagnosis and also help early diagnosis. The RA33 antibody was not associated with RF, and the positive rate of RA33 antibody in RF-negative patients was 27% to 45%. Those with positive anti-RA33 were milder, but whether they showed self-limiting and good prognosis, further study is needed. In addition, the anti-RA33 positive rate of RA patients was significantly higher than that of patients with medication, suggesting that chronic anti-rheumatic drugs may affect the anti-RA33 positive rate. The positive rate of anti-RA33 in other rheumatism patients was higher in SLE, which was 14.8%, all female. It has been reported that the antibody-positive SLE patients have more erosive arthritis, and skin involvement is less common. The antibody was not found to be associated with these clinical features, but these patients were significantly associated with anti-Sm, anti-RNP, and ANA in serology. This contributes to the differential diagnosis of RA. Therefore, simultaneous detection of antibodies against Sm, anti-RNP, ANA, etc., helps to identify the significance of anti-RA33 positivity and improve the specificity for RA. Although RA33 antibodies are present in a variety of connective tissue diseases (probably RA33 cross-reacts with anti-U1RNP antibodies), there is controversy about the diagnostic specificity of RA, but combined with clinical features and other laboratory tests, such as RA, generally do not have a mix. The high titer U1RNP antibody unique to patients with connective tissue disease does not have the specific double-stranded DNA and Sm antibodies commonly found in patients with systemic lupus erythematosus. There is no RA33 antibody in osteoarthritis, ankylosing spondylitis, and psoriatic arthritis. Therefore, RA33 antibody is still considered to be a useful indicator for the identification of RA and other arthritis. Precautions A small number of SSc were positive. Inspection process Same as immunoblotting. Not suitable for the crowd There are no taboos. Adverse reactions and risks There are no related complications and hazards.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.